FDA defers action on Novartis|BeiGene''s tislelizumab for esophagus cancer citing inspection woes
The U.S. Food and Drug Administration ((FDA)) deferred action on approving BeiGene (BGNE) and Novartis'' (NVS) tislelizumab for esophageal cancer as the agency was unable to carry…
FDA defers action on Novartis|BeiGene''s tislelizumab for esophagus cancer citing inspection woes
The U.S. Food and Drug Administration ((FDA)) deferred action on approving BeiGene (BGNE) and Novartis'' (NVS) tislelizumab for esophageal cancer as the agency was unable to carry…